


# Greenwich Clinical Matters

## MEDICINES MANAGEMENT

### Changes on Community Pharmacist Consultation Service (CPCS)

EMIS is in the process of updating the Patient Access Connect. The 'Patient Signposting' Icon will be replaced with 'Local Service' Icon.



It can be accessed the same way as Patient Access Connect for creating referral and assessing for referral. This new icon will automatically generate a SNOMED code of 'Referral to Community Pharmacist Consultation Service (CPCS)' once a referral has been made successfully.

**Action:** Please read **Attachment 1** for the updated GP implementation checklist for CPCS.

### NHS Discharge Medicines Service (DMS)

This is an essential service for community pharmacy contractors, launched in February 2021. By referring patients to their nominated community pharmacy on discharge with information about medication changes made in hospital, community pharmacy can support patients to improve outcomes, prevent harm and reduce readmissions. Discharge from hospital is associated with increased risk of [avoidable medication-related harm](#). The NHS DMS does not replace the role of general practice in managing patients' medicines on discharge (e.g. reconciling medicines with the general practice clinical IT system). **From the 1 April 2022 Queen Elizabeth Hospital, Lewisham and Greenwich Trust, have started referring patients electronically to NHS DMS as part of 2022-23 CQUIN requirements for NHS Trusts.**

**Action:** See more recommendations on [NICE guideline NG05](#). See **Attachment 2** for more information about the new NHS DMS and relevant pathway.

### OptimiseRx user forum

A South East London OptimiseRx user forum is being set up to provide an opportunity for practices to provide structured feedback on what is working well and what can be improved with OptimiseRx. We are looking for one user representative from Greenwich, who can either be a clinician or practice pharmacist. The OptimiseRx user forum meetings would take place quarterly and feature topics such as rejected messages, new changes and frequency of practice reports. The main purpose of the forum is for practices to have a platform to provide structured feedback on what is working well and what can be improved. If you are interested, please email [GRECCG.Pharmacy@nhs.net](mailto:GRECCG.Pharmacy@nhs.net) before 30/06/22.

## MEDICINES MANAGEMENT

### Drug Safety Update

#### Pregabalin (Lyrica): findings of safety study on risks during pregnancy

A new study has suggested pregabalin may slightly increase the risk of major congenital malformations if used in pregnancy. Patients should continue to use effective contraception during treatment and avoid use in pregnancy unless clearly necessary. For more information click [here](#).

### Out of Stock Update

#### Glycerol 1g and 4g suppositories

Glycerol 1g suppositories are out of stock until mid-June 2022. Glycerol 4g suppositories are in limited supply until mid-May 2022. Glycerol 2g suppositories remain available and can support an increase in demand.

**Action:** Prescribers should consider prescribing half a 2g suppository in infants who require a 1g dose and where relevant, advise parents/carers to cut the suppository lengthways to ensure a more accurate dose is administered.

#### Hormone Replacement Therapy (HRT) shortages

HRT availability varies currently. For product availability, Click [here](#)

**Action:** Limit dispensing to 3 months' supply of Oestrogel®, Ovestin® cream and Premique Low Dose® to ensure to more reliable access to hormone replacement therapy (HRT) products

#### Atrial fibrillation and DOAC webinar - 29 June 2022: 1– 2pm

This course is aimed at GPs, nurse prescribers, PCN and practice pharmacists and pharmacy technicians, Medicines Optimisation teams and community pharmacists and it is aimed at improving patient care and ensuring safe prescribing.

Speakers: Rachel Howatson, Senior CVD Pharmacist, SEL CCG, Helen Williams, Consultant Pharmacist for CVD, SEL CCG and National Specialty Adviser for CVD Prevention, NHSE&I. For further information and to join the webinar see

#### Appendix 3

#### Saxenda Pathway

Saxenda (Liraglutide) is approved by NICE for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, **only if:**

- Within the specified parameters (BMI, HbA1c and CVD risk); **and**
- it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service; **and** the company provides it according to the commercial arrangement.

In SEL, it is **RED** due to the commercial arrangement being only available for tier 3 service providers. (cont'd)

## MEDICINES MANAGEMENT

### Saxenda pathway (continued)

Referral for eligible patients to The Bariatric Consultancy is available from 1 June 2022 onwards for Greenwich patients, please refer to the pathway for referral criteria. (*See Appendix 4*).

### SEL formulary Traffic Light Status Prescribing

The SEL Joint Medicines Formulary details medicine's indications for use and contain useful links to SEL guidance and NICE guidelines.

The status of Amber 2 drugs on the Traffic Light Status information indicates that the relevant medicine is for Specialist initiation then continuation in primary care under an individual management plan. An Amber 3 drug indicates that the medicine is for Specialist initiation and after dose stabilisation, GPs would be requested to take over prescribing responsibilities using the approved IMOC shared care documentation.

**Action:** For more information, please visit

[South East London Joint Medicines Formulary \(selondonjointmedicinesformulary.nhs.uk\)](https://selondonjointmedicinesformulary.nhs.uk) and [The-South-East-London-Red-Amber-Green-Grey-List-background-and-definitions.pdf \(selondonccg.nhs.uk\)](https://selondonccg.nhs.uk/definitions.pdf)

### Dietitian Led- SEL Non-IgE Cow's Milk Allergy Rapid Access Clinic (patients with delayed symptoms)

The SEL Prescribing Support Dietetic service runs a weekly **Non-IgE** Cows' Milk Allergy Rapid Access Clinic (SEL CMA RAC) telephone clinic. This clinic helps to support GPs with the diagnosis and management of patients with **suspected non-IgE CMA (delayed symptoms)**.

A simplified referral form with a new tool for use by GPs to support CMA assessment (Allergy Focused Clinical Form) to be completed during consultation is now available.

**Action:**

- Please refer as soon as you suspect non-IgE CMA in your patients.
- **Refer via e-RS only.** Our service is listed under Speciality: Dietetics, Clinic Type: Food Allergy and Intolerance.
- The referral form can be found under SEL CCG subscription: Nutrition and Dietetics/Referral on DXS. (Document number SEL1321)

If you have any questions, please contact [gst-tr.prescribingsupportdietitians@nhs.net](mailto:gst-tr.prescribingsupportdietitians@nhs.net)

## SYSTEM DEVELOPMENT: DIABETES

### Healthy Eating and Active Lifestyles for Diabetes (HEAL-D) in African and Caribbean communities

Since December 2021, Diabetes Book & Learn have been offering a bespoke self-management group education course for people with type 2 diabetes from African and Caribbean communities.

**Action:**

- HEAL-D integrates evidence-based behaviour change techniques, dietary counselling, and exercise classes. Find out more [here](#).
- Referrals to HEAL-D can be made using the Diabetes Book & Learn referral form within DXS/EMIS. See **Attachment 5** for more information.

## MEDICINES MANAGEMENT

### SEL Integrated Medicines Optimisation Committee (IMOC)

The following IMOC decisions/outputs are now available and can be accessed via the links:

#### NEW

- [Formulary recommendation 132](#) for rivaroxaban 1mg/ml granules for oral suspension and 2.5mg, 15mg and 20mg tablets for the treatment of venous thromboembolism in paediatrics as **red** (*suitable for prescribing and supply by hospital only*). This is a time limited approval and certain criteria apply for use of rivaroxaban in this patient cohort – please refer to the [formulary recommendation](#) for further details.

#### UPDATED

- [Position statement 002](#) for Sativex™ oromucosal spray for the treatment of moderate to severe spasticity due to multiple sclerosis in adults has been updated following the presentation of a report on usage and implementation. Please refer to the [formulary recommendation](#) for further detail.
- [Formulary recommendation 119](#) for botulinum toxin type A for spasmodic dysphonia (laryngeal dystonia) in adults has been updated following the presentation of outcome data. Please refer to the [formulary recommendation](#) for further detail.
- [Formulary update](#) to clonazepam tablets for the management of REM sleep disorders (off-label use). In addition to Sleep Centre specialists, Parkinson's disease consultants have now been included as initiating clinicians, in line with [NICE guidance](#). Please refer to the [SEL Joint Medicine Formulary](#) for further information.

## MEDICINES MANAGEMENT

### South East London (SEL) Malnutrition and Appropriate Prescribing Guidelines.

These new guidelines are intended to provide information and guidance on current best practice, reduce unnecessary expenditure and to ensure a consistent approach to the management of malnutrition across South East London (SEL) for use by primary care clinicians who may need to initiate ONS prior to a patient being assessed by a dietitian.

If you would like a bespoke update for your team, please contact [gst-tr.prescribingsupportdietitians@nhs.net](mailto:gst-tr.prescribingsupportdietitians@nhs.net)

**Action:**

Join Q&A sessions hosted by the SEL Prescribing Support Dietetic Service every Thursday 1300-1330 until the 30<sup>th</sup> of June 2022. Please feel free to drop in via the link below and ask us any questions you have regarding:

- The new SEL Malnutrition and Appropriate ONS Prescribing Guidelines
- Adult oral nutritional supplements
- The management of malnutrition

[Click here to join the meeting](#)

## Contact Details

**Meds Management:** [greccg.pharmacy@nhs.net](mailto:greccg.pharmacy@nhs.net) (020 3049 9000)

**Primary Care:** Jan Matthews: [jan.matthews@nhs.net](mailto:jan.matthews@nhs.net)

**System Development:** Jo Hare: [joannehare@nhs.net](mailto:joannehare@nhs.net)